Vancomycin Exposure and Acute Kidney Injury Outcome: A Snapshot From the CAMERA2 Study
Jiajun Liu, Steven Y. C. Tong, Joshua S. Davis, Nathaniel J. Rhodes, Marc H. Scheetz, CAMERA2 Study Group, Nick Anagostou, David Andresen, Sophia Archuleta, Narin Bak, Alan Cass, Mark D. Chatfield, Alan Cheng, Jane Davies, Joshua S. Davis, Yael Dishon, Ravindra Dotel, Patricia E. Ferguson, Hong Foo, Vance G. Fowler, Niladri Ghosh, Timothy Gray, Stephen Guy, Natasha E. Holmes, Benjamin P. Howden, Sandra Johnson, Shirin Kalimuddin, David Chien Lye, Stephen McBride, Genevieve McKew, Niamh Meagher, Jane Nelson, Matthew O’Sullivan, David L. Paterson, Mical Paul, David Price, Anna P. Ralph, Matthew J. Roberts, Owen Robinson, Benjamin A. Rogers, Naomi Runnegar, Simon Smith, Archana Sud, Steven Y. C. Tong, Adrian R Tramontana, Sebastian van Hal, Genevieve Walls, Morgyn S. Warner, Dafna Yahav, Barnaby Edward Young
Abstract
Abstract Among patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteremia from a prospective randomized clinical trial, acute kidney injury (AKI) rates increased with increasing vancomycin exposure, even within the therapeutic range. AKI was independently more common for the (flu)cloxacillin group. Day 2 vancomycin AUC ≥470 mg·h/L was significantly associated with AKI, independent of (flu)cloxacillin receipt.